Clinical Trials

28 enrolled

Adenocarcinoma of Endometrium

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

50 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01602380 2026-02-27

FALCON

462 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

99 enrolled 61 charts

Advanced Metastatic Breast Cancer

NCT05022342 2026-02-23

SPEAR

Completed

595 enrolled

Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

19 enrolled 10 charts

Breast Neoplasms

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

100 enrolled

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04603183 2025-12-12

ABIGAIL

162 enrolled

Breast Cancer Metastatic

NCT05631795 2025-12-03

ALPINIST

Phase 4 Completed

40 enrolled

Endocrine

Multiple Endocrine Neoplasia Type 1

NCT02630693 2025-11-25

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

180 enrolled 14 charts

Breast Neoplasms

NCT03363893 2025-11-12

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

124 enrolled

Tumor-Agnostic

Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

144 enrolled 25 charts

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT02958852 2025-09-10

ABC-SE

126 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT07096024 2025-08-28

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

Completed

1,772 enrolled

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

62 enrolled 18 charts

Breast Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT01441947 2025-05-25

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

68 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05054374 2025-05-23

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

6 enrolled 4 charts

Breast Neoplasms

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

20 enrolled

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06525675 2024-12-13

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Completed

419 enrolled

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

486 enrolled 15 charts

Breast Neoplasms

NCT02632045 2024-12-06

MAINTAIN

169 enrolled 12 charts

Breast Neoplasms

NCT02216786 2024-12-02

MANTA

333 enrolled

Estrogen Receptor Positive Breast Cancer

NCT02675231 2024-11-26

monarcHER

237 enrolled 25 charts

Hormone Receptor Positive Breast Cancer

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

35 enrolled 19 charts

Breast Neoplasms

NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

275 enrolled

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

7 enrolled 13 charts

Breast Neoplasms

NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

225 enrolled 31 charts

Advanced Cancer

NCT03439046 2024-08-01

BioItaLEE

287 enrolled

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02599714 2024-06-06

PASTOR

54 enrolled

Breast Neoplasms

NCT03926936 2024-05-28

FUCHSia

17 enrolled

GynecologicSarcoma

Adenosarcoma of the uterus, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sex Cord-Gonadal Stromal Tumors

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts

Breast Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT02536742 2024-02-26

PYTHIA

124 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT01142401 2023-11-27

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

118 enrolled 11 charts

Breast Neoplasms

NCT03481998 2023-11-21

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

104 enrolled

Breast Neoplasms

NCT06074757 2023-10-10

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

48 enrolled

Breast Neoplasms

NCT03809988 2023-09-07

PALMIRA

198 enrolled

Breast Neoplasms

NCT03555877 2023-07-07

AMICA

56 enrolled

Breast Cancer Metastatic

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

88 enrolled